Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18919069 | ANTIGEN BINDING POLYPEPTIDES | October 2024 | January 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18887598 | ANTIBODIES SPECIFICALLY BINDING TO CD147 AND USES THEREOF | September 2024 | March 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18307299 | ANTIBODIES BINDING BCMA AND CD3 AND USES THEREOF | April 2023 | May 2024 | Allow | 12 | 1 | 1 | No | No |
| 18119103 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF CANCER | March 2023 | October 2024 | Abandon | 20 | 1 | 0 | No | No |
| 18154597 | TM4SF5-TARGETING HUMANIZED ANTIBODY AND USE THEREOF | January 2023 | June 2024 | Allow | 17 | 1 | 1 | Yes | No |
| 18089393 | BINDING MOLECULE ABLE TO NEUTRALIZE PROX1 PROTEIN | December 2022 | May 2024 | Allow | 17 | 1 | 1 | Yes | No |
| 17592105 | FORMULATIONS AND PROCESSES FOR CAR T CELL DRUG PRODUCTS | February 2022 | January 2025 | Allow | 35 | 2 | 0 | No | Yes |
| 17490582 | MODIFIED CELL AND USE THEREOF IN GENE AND CELL THERAPY | September 2021 | November 2023 | Allow | 25 | 0 | 0 | Yes | No |
| 17598737 | Efflux Pump-Cancer Antigen Multi-Specific Antibodies and Compositions, Reagents, Kits and Methods Related Thereto | September 2021 | February 2025 | Allow | 41 | 1 | 0 | No | No |
| 17442939 | ANTI-CLAUDIN 18.2 ANTIBODY AND APPLICATION THEREOF | September 2021 | May 2025 | Allow | 44 | 1 | 0 | No | No |
| 17436951 | THREONINE166 AND SERINE189 OF RUBICON RUN DOMAIN AS LRRK2 KINASE INHIBITION TARGET SITES | September 2021 | February 2025 | Allow | 41 | 1 | 0 | No | No |
| 17435387 | LILRB4-BINDING ANTIBODY AND METHODS OF USE THEREOF | August 2021 | August 2024 | Allow | 36 | 0 | 0 | Yes | No |
| 17430144 | BISPECIFIC ANTIBODY SPECIFICALLY BINDING TO IL-17A AND TNF-Alpha | August 2021 | September 2024 | Allow | 37 | 0 | 1 | Yes | No |
| 17429584 | MODULATION OF WNT SIGNALLING IN OCULAR DISORDERS | August 2021 | March 2025 | Allow | 43 | 1 | 0 | Yes | No |
| 17429208 | ANTI-ANG2 ANTIBODY AND USE THEREOF | August 2021 | January 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17395996 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | August 2021 | July 2024 | Allow | 35 | 0 | 0 | Yes | No |
| 17428816 | ANTIBODIES AGAINST hEPCR | August 2021 | October 2024 | Allow | 38 | 0 | 1 | Yes | No |
| 17428079 | TREATMENT OF CUTANEOUS T CELL LYMPHOMA WITH TARGETING OF CD47 PATHWAY | August 2021 | April 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17380251 | Therapeutic RNA and Anti-PD1 Antibodies for Advanced Stage Solid Tumor Cancers | July 2021 | January 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17423344 | Method for Counting Cell Types or Cell Markers In a Sample, In Particular In a Blood Sample | July 2021 | January 2025 | Allow | 42 | 1 | 0 | No | No |
| 17353617 | Humanized Anti-PD-1 Antibody and The Use Thereof | June 2021 | June 2024 | Allow | 35 | 0 | 0 | Yes | No |
| 17055799 | COMPLEX HAVING ANTI-HUMAN MUC1 ANTIBODY FAB FRAGMENT, PEPTIDE LINKER AND/OR LIGAND | June 2021 | November 2024 | Allow | 48 | 2 | 0 | No | No |
| 17312523 | METHODS AND COMPOSITIONS RELATING TO IMPROVED FORMS OF TARGETED ERYTHROPOIETIN | June 2021 | December 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17342513 | T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use Thereof | June 2021 | May 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17311258 | Humanized and Affinity-Matured Anti-CEACAM1 Antibodies | June 2021 | August 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17299086 | ANTI-C-MET AGONIST ANTIBODY AND USE THEREOF | June 2021 | August 2024 | Allow | 38 | 1 | 0 | No | No |
| 17299274 | LONG-ACTING EXENDIN-4 AND USE THEREOF | June 2021 | August 2024 | Allow | 39 | 1 | 0 | Yes | No |
| 17291701 | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES | May 2021 | September 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17291198 | ANTI-LIV1 IMMUNE CELL CANCER THERAPY | May 2021 | February 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17290480 | ANTI-TNFALPHA/ANTI IL - 17A NATURAL ANTIBODY STRUCTURE-LIKE HETERODIMER FORM OF BISPECIFIC ANTIBODY AND PREPARATION METHOD THEREFOR | April 2021 | February 2025 | Allow | 45 | 2 | 1 | No | No |
| 17287462 | Anti-B7-H4 Chimeric Antigen Receptor-Modified NK-92 Cells | April 2021 | August 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17284946 | Targeting the Non-Canonical NFkB Pathway in Cancer Immunotherapy | April 2021 | October 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17284948 | METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER | April 2021 | June 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17229856 | COMBINATION INCLUDING A CPG-C TYPE OLIGONUCLEOTIDE AND A PD-1 ANTAGONIST FOR TREATING BREAST CANCER | April 2021 | October 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17284672 | NOVEL ANTI-C-KIT ANTIBODY | April 2021 | August 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17283434 | ANTIBODIES AND THERAPEUTIC USES THEREOF | April 2021 | August 2024 | Allow | 40 | 0 | 0 | Yes | No |
| 17281372 | COMBINATION THERAPY OF CLDN18 ANTIBODY AND CHEMOTHERAPY DRUGS | March 2021 | September 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17281058 | PDGF RECEPTOR ANTIBODY AND USE THEREOF | March 2021 | May 2024 | Allow | 38 | 0 | 1 | Yes | No |
| 17280766 | CSF1R/CCR2 MULTISPECIFIC ANTIBODIES | March 2021 | March 2025 | Abandon | 48 | 2 | 1 | Yes | No |
| 17276553 | ANTI-LMP2 TCR-T CELL THERAPY FOR THE TREATMENT OF EBV-ASSOCIATED CANCERS | March 2021 | July 2024 | Allow | 40 | 1 | 0 | No | No |
| 17275140 | METHODS OF MODULATING ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY | March 2021 | March 2025 | Abandon | 49 | 2 | 0 | No | No |
| 17273172 | SPECIFIC MONOCLONAL ANTIBODY AGAINST THE N ANTIGEN OF HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) USEFUL FOR TREATING INFECTION, DETECTION THEREOF AND DIAGNOSIS | March 2021 | April 2024 | Allow | 37 | 1 | 0 | Yes | No |
| 17273082 | METHODS AND COMPOSITIONS FOR TREATING ASTHMA AND ALLERGIC DISEASES | March 2021 | November 2024 | Allow | 44 | 2 | 1 | Yes | No |
| 17270571 | CHIMERIC ANTIGEN RECEPTOR CELLS FOR TREATING SOLID TUMOR | February 2021 | July 2024 | Allow | 41 | 1 | 0 | Yes | No |
| 17269991 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | February 2021 | June 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17269456 | ANTI-TIM3 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF | February 2021 | October 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17265016 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING POMPE DISEASE | February 2021 | January 2024 | Abandon | 36 | 0 | 1 | No | No |
| 17261998 | METHODS FOR TARGETING, INHIBITING, AND TREATING A TUMORAL MICROENVIRONMENT | January 2021 | May 2025 | Abandon | 52 | 3 | 0 | No | No |
| 17260974 | ANTI-PD-1 ANTIBODIES, DOSAGES AND USES THEREOF | January 2021 | December 2024 | Allow | 47 | 2 | 0 | Yes | No |
| 17251196 | PANCREATIC CANCER DETERMINATION MARKER | December 2020 | February 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17048549 | ANTI-ROR ANTIBODY CONSTRUCTS | October 2020 | May 2024 | Allow | 43 | 0 | 1 | Yes | No |
| 16963047 | COMPOSITIONS AND METHODS FOR TARGETING GAMMA DELTA T CELLS WITH CHIMERIC ANTIGEN RECEPTORS | July 2020 | September 2024 | Allow | 50 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner FAUST, AMBER KATHLEEN.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner FAUST, AMBER KATHLEEN works in Art Unit 1643 and has examined 50 patent applications in our dataset. With an allowance rate of 66.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner FAUST, AMBER KATHLEEN's allowance rate of 66.0% places them in the 19% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by FAUST, AMBER KATHLEEN receive 0.88 office actions before reaching final disposition. This places the examiner in the 9% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by FAUST, AMBER KATHLEEN is 41 months. This places the examiner in the 6% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +57.4% benefit to allowance rate for applications examined by FAUST, AMBER KATHLEEN. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 41.7% of applications are subsequently allowed. This success rate is in the 92% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 100.0% of cases where such amendments are filed. This entry rate is in the 99% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.